Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses SRDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SRDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gary Maharaj | $647,481 | $0 | $940,000 | $1,410,000 | $654,215 | $0 | $13,800 | $3,665,496 |
| President and Chief Executive Officer | ||||||||
| Teryl Sides | 446,844 | 0 | 312,000 | 468,000 | 282,182 | 0 | 12,344 | 1,521,370 |
| Senior Vice President and President, Vascular Interventions | ||||||||
| Timothy Arens | 386,588 | 0 | 280,000 | 420,000 | 244,130 | 0 | 13,793 | 1,344,511 |
| Senior Vice President of Finance and Information Technology and Chief Financial Officer | ||||||||
| Gordon Weber | 361,987 | 0 | 220,000 | 330,000 | 228,595 | 0 | 6,113 | 1,146,695 |
| Senior Vice President of Legal, General Counsel and Secretary | ||||||||
| Charles Olson | 361,987 | 0 | 212,000 | 318,000 | 233,301 | 0 | 8,827 | 1,134,115 |
| Senior Vice President and President, Medical Device Coatings | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Gary Maharaj | $3,665,496 | $3,527,263 | $3,095,627 | +138,233 |
| Teryl Sides | 1,521,370 | 1,494,375 | 1,113,022 | +26,995 |
| Timothy Arens | 1,344,511 | 1,295,299 | 1,045,826 | +49,212 |
| Gordon Weber | 1,146,695 | 1,102,840 | 1,019,595 | +43,855 |
| Charles Olson | 1,134,115 | 1,118,470 | 1,023,119 | +15,645 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gordon Weber | OPTION | 2023-12-04 | — | — | 20,859 | — | $330,000 |
| Charles Olson | OPTION | 2023-12-04 | — | — | 20,101 | — | 318,000 |
| Charles Olson | RSU | 2023-12-04 | — | — | 6,302 | — | 212,000 |
| Gary Maharaj | RSU | 2023-12-04 | — | — | 27,942 | — | 940,000 |
| Teryl Sides | RSU | 2023-12-04 | — | — | 9,274 | — | 312,000 |
| Gordon Weber | RSU | 2023-12-04 | — | — | 6,539 | — | 220,000 |
| Timothy Arens | OPTION | 2023-12-04 | — | — | 26,548 | — | 420,000 |
| Teryl Sides | OPTION | 2023-12-04 | — | — | 29,582 | — | 468,000 |
| Gary Maharaj | OPTION | 2023-12-04 | — | — | 89,127 | — | 1,410,000 |
| Timothy Arens | RSU | 2023-12-04 | — | — | 8,323 | — | 280,000 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gordon Weber | $220,000 | $0 | $330,000 | 0.0% |
| Charles Olson | 212,000 | 0 | 318,000 | 0.0% |
| Gary Maharaj | 940,000 | 0 | 1,410,000 | 0.0% |
| Teryl Sides | 312,000 | 0 | 468,000 | 0.0% |
| Timothy Arens | 280,000 | 0 | 420,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Charles Olson | RSU | 39,915 | — | $2,003,754 |
| Timothy Arens | RSU | 8,323 | — | 322,766 |
| Timothy Arens | RSU | 4,797 | — | 186,028 |
| Gary Maharaj | Option | 18,629 | 37.44 | — |
| Timothy Arens | Option | 26,548 | 33.64 | — |
| Teryl Sides | Option | 29,582 | 33.64 | — |
| Timothy Arens | Option | 9,168 | 43.93 | — |
| Gary Maharaj | RSU | 16,237 | — | 629,671 |
| Gary Maharaj | RSU | 6,070 | — | 235,395 |
| Teryl Sides | RSU | 5,535 | — | 214,647 |
| Timothy Arens | RSU | 1,517 | — | 58,829 |
| Teryl Sides | RSU | 1,517 | — | 58,829 |
| Gary Maharaj | Option | 89,127 | 33.64 | — |
| Timothy Arens | Option | 18,762 | 36.13 | — |
| Gordon Weber | Option | 20,859 | 33.64 | — |
| Teryl Sides | Option | 9,168 | 43.93 | — |
| Charles Olson | RSU | 3,690 | — | 143,098 |
| Gordon Weber | Option | 9,168 | 43.93 | — |
| Gordon Weber | RSU | 3,690 | — | 143,098 |
| Teryl Sides | RSU | 9,274 | — | 359,646 |
| Gordon Weber | Option | 4,471 | 37.44 | — |
| Gary Maharaj | RSU | 27,942 | — | 1,083,591 |
| Charles Olson | Option | 20,101 | 33.64 | — |
| Charles Olson | RSU | 6,302 | — | 244,392 |
| Gordon Weber | RSU | 6,539 | — | 253,582 |
| Gary Maharaj | Option | 63,502 | 36.13 | — |
| Charles Olson | Option | 14,432 | 36.13 | — |
| Gary Maharaj | RSU | 2,977,230 | — | 115,457,005 |
| Gary Maharaj | RSU | 1,374,065 | — | 53,286,253 |
| Timothy Arens | RSU | 1,155,320 | — | 44,803,318 |
| Teryl Sides | RSU | 1,335,396 | — | 51,786,585 |
| Gordon Weber | RSU | 319,247 | — | 12,380,378 |
| Charles Olson | RSU | 1,081,800 | — | 41,952,145 |
| Gordon Weber | RSU | 1,081,800 | — | 41,952,135 |
| Timothy Arens | RSU | 44,275 | — | 2,306,229 |
| Gordon Weber | RSU | 18,123 | — | 702,809 |
| Charles Olson | Option | 4,471 | 37.44 | — |
| Teryl Sides | Option | 4,471 | 37.44 | — |
| Charles Olson | RSU | 1,517 | — | 58,829 |
| Gordon Weber | Option | 14,432 | 36.13 | — |
| Teryl Sides | RSU | 450,468 | — | 17,469,125 |
| Timothy Arens | Option | 4,471 | 37.44 | — |
| Charles Olson | Option | 9,168 | 43.93 | — |
| Gordon Weber | RSU | 1,517 | — | 58,829 |
| Gary Maharaj | Option | 36,674 | 43.93 | — |
| Charles Olson | RSU | 312,152 | — | 12,105,238 |
| Teryl Sides | Option | 21,648 | 36.13 | — |
| Gary Maharaj | RSU | 40,093 | — | 1,554,807 |
| Timothy Arens | RSU | 402,243 | — | 15,598,986 |
| Teryl Sides | RSU | 42,502 | — | 2,605,384 |
Our compensation philosophy is performance-based and focuses on aligning the financial interests of our executive officers with those of our shareholders. Generally, this is accomplished by placing a substantial portion of our executive officers' total compensation "at risk", while providing overall compensation opportunities that are comparable to market levels.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-02-06 | 7,415,339 | 1,043,557 | 132,993 | 87.66% | Passed |
| 2024 | 2024-02-08 | 9,588,433 | 650,245 | 10,353 | 93.65% | Passed |
| 2023 | 2023-02-09 | 11,173,618 | 669,818 | 16,655 | 94.34% | Passed |
| 2022 | 2022-02-10 | 11,084,992 | 591,658 | 16,826 | 94.93% | Passed |
| 2021 | 2021-02-11 | 11,234,762 | 274,983 | 42,478 | 97.61% | Passed |
| 2020 | 2020-02-13 | 10,662,542 | 296,400 | 82,208 | 97.3% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-02-06 | 87.66%a |
| 2024 | 2024-02-08 | 93.65%b |
| 2023 | 2023-02-09 | 94.34%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Susan E. KnightIndependent · Board Chair · Audit (Chair) | $110,000 | $62,000 | $62,000 | — | $0 | $234,000 |
| David R. Dantzker, M.DIndependent · Organization and Compensation (Chair) · Corporate Governance and Nominating · Audit | 70,000 | 57,500 | 57,500 | — | 0 | 185,000 |
| Lisa W. HeineIndependent · Organization and Compensation · Corporate Governance and Nominating · Audit | 66,500 | 57,500 | 57,500 | — | 0 | 181,500 |
| José H. BedoyaIndependent · Corporate Governance and Nominating (Chair) · Organization and Compensation | 61,500 | 57,500 | 57,500 | — | 0 | 176,500 |
| Ronald B. KalichIndependent · Departed during FY | 58,250 | 57,500 | 57,500 | — | 0 | 173,250 |
| Gary R. MaharajEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $115,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 10,000 |
| Stock ownership guideline | 5x annual cash retainer for non-employee directors |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $366,250 |
| Equity awards (grant-date value) | $292,000 |
| All other compensation | $0 |
| Total cost of the board | $658,250 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Surmodics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Surmodics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AtriCure, Inc. | 2025 | Michael Carrel | $828,439 | $7,203,478 | $0 | $1,171,703 | $9,217,620 |
| 2 | AxoGen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 3 | SI-BONE, Inc. | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 4 | Cutera, Inc. | 2023 | Taylor Harris | 271,023 | 2,747,682 | 4,250,008 | 0 | 7,279,813 |
| 5 | Artivion Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 6 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 7 | Cerus Corporation | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
| 8 | LeMaitre Vascular, Inc. | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 9 | Surmodics | 2024 | Gary Maharaj | 647,481 | 940,000 | 1,410,000 | 654,215 | 3,665,496 |
| 10 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 11 | Anika Therapeutics Inc. | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
| 12 | Atrion Corp. | 2023 | David Battat | 718,077 | 0 | 0 | 180,000 | 924,464 |
| — | Xtant Medical Holdings, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cardiovascular Systems Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Conformis, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Pulmonx Corporation | — | — | — | — | — | — | not in coverage universe |
| — | NeuroPace, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Surmodics | 126.3% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Anika Therapeutics Inc. | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Artivion Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Atrion Corp. | 25% | RSU 100 | not disclosed | FW Cook |
| AxoGen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Cardiovascular Systems Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cerus Corporation | 126% | RSU 75 · PSU 25 | No | Alpine |
| Conformis, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cutera, Inc. | not disclosed | not disclosed | No | Compensia |
| LeMaitre Vascular, Inc. | 144% | Options 50 · RSU 25 · PSU 25 | No | not disclosed |
| NeuroPace, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance LLC |
| Pulmonx Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| SI-BONE, Inc. | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Xtant Medical Holdings, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gary Maharaj | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Summary Compensation Table” · page 37. As printed: 3,665,496. Filing ↗machine: t109 · r3 · c25 · span 1568790–1568799 |
| 2 | Section 01, Teryl Sides | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Summary Compensation Table” · page 37. As printed: 1,521,370. Filing ↗machine: t109 · r12 · c25 · span 1649599–1649608 |
| 3 | Section 01, Timothy Arens | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Summary Compensation Table” · page 37. As printed: 1,344,511. Filing ↗machine: t109 · r6 · c25 · span 1595678–1595687 |
| 4 | Section 01, Gordon Weber | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Summary Compensation Table” · page 37. As printed: 1,146,695. Filing ↗machine: t109 · r15 · c25 · span 1676541–1676550 |
| 5 | Section 01, Charles Olson | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Summary Compensation Table” · page 37. As printed: 1,134,115. Filing ↗machine: t109 · r9 · c25 · span 1622649–1622658 |
| 6 | Section 03, Gordon Weber OPTION | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r18 · c20 · span 1880537–1880543 |
| 7 | Section 03, Charles Olson OPTION | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r12 · c20 · span 1824523–1824529 |
| 8 | Section 03, Charles Olson RSU | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r11 · c17 · span 1814186–1814191 |
| 9 | Section 03, Gary Maharaj RSU | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r5 · c17 · span 1758186–1758192 |
| 10 | Section 03, Teryl Sides RSU | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r14 · c17 · span 1842194–1842199 |
| 11 | Section 03, Gordon Weber RSU | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r17 · c17 · span 1870200–1870205 |
| 12 | Section 03, Timothy Arens OPTION | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r9 · c20 · span 1796516–1796522 |
| 13 | Section 03, Teryl Sides OPTION | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r15 · c20 · span 1852531–1852537 |
| 14 | Section 03, Gary Maharaj OPTION | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r6 · c20 · span 1768507–1768513 |
| 15 | Section 03, Timothy Arens RSU | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r8 · c17 · span 1786179–1786184 |
| 16 | Section 08, Susan E. Knight | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 234,000. Filing ↗machine: t50 · r3 · c15 · span 556603–556610 |
| 17 | Section 08, David R. Dantzker, M.D | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 185,000. Filing ↗machine: t50 · r5 · c15 · span 567845–567852 |
| 18 | Section 08, Lisa W. Heine | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 181,500. Filing ↗machine: t50 · r6 · c15 · span 573458–573465 |
| 19 | Section 08, José H. Bedoya | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 176,500. Filing ↗machine: t50 · r4 · c15 · span 562222–562229 |
| 20 | Section 08, Ronald B. Kalich | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 173,250. Filing ↗machine: t50 · r7 · c15 · span 579234–579241 |
| 21 | Section 08, Gary R. Maharaj | DEF 14A | 2024-12-19 | 0000950170-24-138240 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 06, 2025 vote | Form 8-K | 2025-02-10 | 0000950170-25-016772 | Item 5.07 · say-on-pay result. As reported: 87.66% (votes for as printed: 7,415,339). Filing ↗ |
| 23 | Section 06, 2024 vote | Form 8-K | 2024-02-12 | 0000950170-24-013859 | Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 9,588,433). Filing ↗ |
| 24 | Section 06, 2023 vote | Form 8-K | 2023-02-13 | 0001157523-23-000265 | Item 5.07 · say-on-pay result. As reported: 94.34% (votes for as printed: 11,173,618). Filing ↗ |
| 25 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 26 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 27 | Section 09b board cost (computed) | Computed | — | computed | Cash 366,250 + equity 292,000 + all other 0 = 658,250, summed across the director compensation table rows.machine: formula: Σ = 658,250 |
| 28 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 29 | AxoGen, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0000805928-26-000057 | CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318 |
| 30 | SI-BONE, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001459839-26-000049 | CEO total compensation as printed in SI-BONE, Inc.'s own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978 |
| 31 | Cutera, Inc., Section 10b CEO total | DEF 14A | 2024-06-17 | 0001628280-24-028528 | CEO total compensation as printed in Cutera, Inc.'s own proxy. As printed: 7,279,813. Filing ↗machine: t62 · r4 · c26 · span 1221355–1221364 |
| 32 | Artivion Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 33 | OraSure Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 34 | Cerus Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001020214-26-000011 | CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. Filing ↗machine: span 1301658–1301667 |
| 35 | LeMaitre Vascular, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-153877 | CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: span 564038–564047 |
| 36 | Surmodics (subject), Section 10b CEO total | DEF 14A | 2024-12-19 | 0000950170-24-138240 | CEO total compensation as printed in Surmodics's own proxy. As printed: 3,665,496. Filing ↗machine: t109 · r3 · c25 · span 1568790–1568799 |
| 37 | Tactile Systems Technology, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001104659-26-034206 | CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806 |
| 38 | Anika Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017488 | CEO total compensation as printed in Anika Therapeutics Inc.'s own proxy. As printed: 2,033,370. Filing ↗machine: r5 · c22 · span 1052517–1052526 |
| 39 | Atrion Corp., Section 10b CEO total | DEF 14A | 2024-04-09 | 0001104659-24-044922 | CEO total compensation as printed in Atrion Corp.'s own proxy. As printed: 924,464. Filing ↗machine: r12 · c47 · span 467910–467917 |
| 40 | Section 10a, Anika Therapeutics Inc. reciprocity | DEF 14A | — | 0001140361-26-017488 | Anika Therapeutics Inc. names Surmodics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 41 | Section 10a, Cerus Corporation reciprocity | DEF 14A | — | 0001020214-26-000011 | Cerus Corporation's most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 42 | Section 10a, OraSure Technologies, Inc. reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 43 | Section 10a, Tactile Systems Technology, Inc. reciprocity | DEF 14A | — | 0001104659-26-034206 | Tactile Systems Technology, Inc. names Surmodics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 44 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 45 | Section 10a, Cutera, Inc. reciprocity | DEF 14A | — | 0001628280-24-028528 | Cutera, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 46 | Section 10a, SI-BONE, Inc. reciprocity | DEF 14A | — | 0001459839-26-000049 | SI-BONE, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 47 | Section 10a, Artivion Inc. reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |
| 48 | Section 10a, AxoGen, Inc. reciprocity | DEF 14A | — | 0000805928-26-000057 | AxoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗ |